Claims
- 1. A compound selected from the group consisting of 11.beta.-(4-dimethylamino-phenyl)-13.beta.-ethyl-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -gonadiene-17.beta.-ol-3-one, 11.beta.-(4-dimethylamino-phenyl)-17.alpha.-(3-hydroxy-prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one, 11.beta.-(4-aminophenyl)-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one, 11.beta.-(4-methylamino-phenyl)-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one, N-[4-{17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one-11.beta.-yl}]-phenyl-acetamide, 11.beta.-(4-dimethylamino-phenyl)-19-nor-17.alpha.-.DELTA..sup.4,9 -pregnadiene-17.beta.-ol-3-one-20-yne-21-carboxylic acid and its salts with non-toxic, pharmaceutically acceptable cations and their non-toxic, pharmaceutically acceptable acid addition salts.
- 2. A compound of claim 1 selected from the group consisting of 11.beta.-(4-dimethylamino-phenyl)-13.beta.-ethyl-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -gonadiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 3. A compound of claim 1 selected from the group consisting of 11.beta.-(4-dimethylamino-phenyl)-17.alpha.-(3-hydroxy-prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 4. A compound of claim 1 selected from the group consisting of 11.beta.-(4-amino-phenyl)-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 5. A compound of claim 1 selected from the group consisting of 11.beta.-(4-methylamino-phenyl)-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 6. A compound of claim 1 selected from the group consisting of N-[4-{17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one-11.beta.-yl}]-phenyl-acetamide and its non-toxic, pharmaceutically acceptable acid addition salts.
- 7. A compound of claim 1 selected from the group consisting of 11.beta.-(4-dimethylamino-phenyl)-19-nor-17.alpha.-.DELTA..sup.4,9 -pregnadiene-17.beta.-ol-3-one 20-yne-21-carboxylic acid and its salts thereof with non-toxic, pharmaceutically acceptable cations and its non-toxic, pharmaceutically acceptable acid addition salts.
- 8. An antiprogestomimetic composition comprising an antiprogestomimetically effective amount of at least one compound of claim 1 and an inert pharmaceutical carrier.
- 9. A composition of claim 8 wherein the compound is selected from the group consisting of 11.beta.-(4-dimethylaminophenyl)-13.beta.-ethyl-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -gonadiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 10. A composition of claim 8 wherein the compound is selected from the group consisting of 11.beta.-(4-dimethylaminophenyl)-17.alpha.-(3-hydroxy-prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 11. A composition of claim 8 wherein the compound is selected from the group consisting of 11.beta.-(4-amino-phenyl)-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 12. A composition of claim 8 wherein the compound is selected from the group consisting of 11.beta.-(4-methylamino-phenyl)-17.alpha.- (prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 13. A composition of claim 8 wherein the compound is selected from the group consisting of N-[4-{17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one-11.beta.-yl}]-phenyl-acetamide and its non-toxic, pharmaceutically acceptable acid addition salts.
- 14. A composition of claim 8 wherein the compound is selected from the group consisting of 11.beta.-(4-dimethylaminophenyl)-19-nor-17.alpha.-.DELTA..sup.4,9 -pregnadiene-17.beta.-ol-3-one 20-yne-21-carboxylic acid and its salts thereof with non-toxic, pharmaceutically acceptable cations and its non-toxic, pharmaceutically acceptable acid addition salts.
- 15. A method of inducing menses in warm-blooded animals comprising administering to warm-blooded animals an antiprogestomimetically effective amount of at least one compound of claim 1.
- 16. A method of claim 15 wherein the compound is selected from the group consisting of 11.beta.-(4-dimethylaminophenyl)-13.beta.-ethyl-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -gonadiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 17. A method of claim 15 wherein the compound is selected from the group consisting of 11.beta.-(4-dimethylamino-phenyl)-17.alpha.-(3-hydroxy-prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 18. A method of claim 15 wherein the compound is selected from the group consisting of 11.beta.-(4-amino-phenyl)-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 19. A method of claim 15 wherein the compound is selected from the group consisting of 11.beta.-(4-methylamino-phenyl)-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 20. A method of claim 15 wherein the compound is selected from the group consisting of N-[4-{17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one-11.beta.-yl}]-phenyl-acetamide and its non-toxic, pharmaceutically acceptable acid addition salts.
- 21. A method of claim 15 wherein the compound is selected from the group consisting of 11.beta.-(4-dimethylamino-phenyl)-19-nor-17.alpha.-.DELTA..sup.4,9 -pregnadiene-17.beta.-ol-3-one 20-yne-21 -carboxylic acid and its salts thereof with non-toxic, pharmaceutically acceptable cations and its non-toxic, pharmaceutically acceptable acid addition salts.
- 22. An antiglucocorticoid composition comprising an antiglucocorticoidally effective amount of at least one compound of claim 1 and an inert pharmaceutical carrier.
- 23. A composition of claim 22 wherein the compound is selected from the group consisting of 11.beta.-(4-dimethylaminophenyl)-13.beta.-ethyl-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -gonadiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 24. A composition of claim 22 wherein the compound is selected from the group consisting of 11.beta.-(4-dimethylaminophenyl)-17.alpha.-(3-hydroxy-prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 25. A composition of claim 22 wherein the compound is selected from the group consisting of 11.beta.-(4-amino-phenyl)-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 26. A composition of claim 22 wherein the compound is selected from the group consisting of 11.beta.-(4-methylamino-phenyl)-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 27. A composition of claim 22 wherein the compound is selected from the group consisting of N-[4-{17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one-11.beta.-yl}]-phenyl-acetamide and its non-toxic, pharmaceutically acceptable acid addition salts.
- 28. A composition of claim 22 wherein the compound is selected from the group consisting of 11.beta.-(4-dimethylaminophenyl)-19-nor-17.alpha.-.DELTA..sup.4,9 -pregnadiene-17.beta.-ol-3-one 20-yne-21-carboxylic acid and its salts thereof with non-toxic, pharmaceutically acceptable cations and its non-toxic, pharmaceutically acceptable acid addition salts.
- 29. A method of inducing antiglucocorticoid activity in warm-blooded animals comprising administering to warm-blooded animals an antiglucocorticoidally effective amount of at least one compound of claim 1.
- 30. A method of claim 29 wherein the compound is selected from the group consisting of 11.beta.-(4-dimethylamino-phenyl)-13.beta.-ethyl-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -gonadiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 31. A method of claim 29 wherein the compound is selected from the group consisting of 11.beta.-(4-dimethylamino-phenyl)-17.alpha.-(3-hydroxy-prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 32. A method of claim 29 wherein the compound is selected from the group consisting of 11.beta.-(4-amino-phenyl)-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 33. A method of claim 29 wherein the compound is selected from the group consisting of 11.beta.-(4-methylamino-phenyl)-17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one and its non-toxic, pharmaceutically acceptable acid addition salts.
- 34. A method of claim 29 wherein the compound is selected from the group consisting of N-[4-{17.alpha.-(prop-1-ynyl)-.DELTA..sup.4,9 -estradiene-17.beta.-ol-3-one-11.beta.-yl}]-phenyl-acetamide and its non-toxic, pharmaceutically acceptable acid addition salts.
- 35. A method of claim 29 wherein the compound is selected from the group consisting of 11.beta.-(4-dimethylamino-phenyl)-19-nor-17.alpha.-.DELTA..sup.4,9 -pregnadiene-17.beta.-ol-3-one 20-yne-21-carboxylic acid and its salts thereof with non-toxic, pharmaceutically acceptable cations and its non-toxic, pharmaceutically acceptable acid addition salts.
Priority Claims (1)
Number |
Date |
Country |
Kind |
81 00272 |
Jan 1981 |
FRX |
|
PRIOR APPLICATION
This application is a continuation-in-part of copending Application Ser. No. 614,440 filed May 25, 1984 now U.S. Pat. No. 4,519,946 which in turn is a division of Application Ser. No. 595,267 filed Mar. 30, 1984 now abandoned which in turn is a division of U.S. patent application Ser. No. 386,967 filed June 10, 1982 now U.S. Pat. No. 4,447,424 which is a continuation-in-part of U.S. patent application Ser. No. 338,077 filed Jan. 9, 1982, now U.S. Pat. No. 4,386,085.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4386085 |
Teutsch et al. |
May 1983 |
|
4447424 |
Teutsch et al. |
May 1984 |
|
Divisions (2)
|
Number |
Date |
Country |
Parent |
595267 |
Mar 1984 |
|
Parent |
386967 |
Jun 1982 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
614440 |
May 1984 |
|
Parent |
338077 |
Jan 1982 |
|